These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17318454)

  • 1. Clinical characterization and risk profile of individuals seeking genetic counseling for hereditary breast cancer in Brazil.
    Palmero EI; Ashton-Prolla P; da Rocha JC; Vargas FR; Kalakun L; Blom MB; Azevedo SJ; Caleffi M; Giugliani R; Schüler-Faccini L
    J Genet Couns; 2007 Jun; 16(3):363-71. PubMed ID: 17318454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
    Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
    Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial breast and ovarian cancer: genetic counseling and clinical management in Italy.
    Pasini B; Pierotti MA
    Dis Markers; 1999 Oct; 15(1-3):41-3. PubMed ID: 10595250
    [No Abstract]   [Full Text] [Related]  

  • 4. [BRCA1- and BRCA2 mutations: Clinical management of patients with hereditary breast and ovarian cancer].
    Pristauz G; Geigl JB; Petru E
    Wien Med Wochenschr; 2010 Apr; 160(7-8):158-62. PubMed ID: 20473725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
    Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
    Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors.
    Berliner JL; Fay AM;
    J Genet Couns; 2007 Jun; 16(3):241-60. PubMed ID: 17508274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of hereditary breast/ovarian cancer risk in patients with a history of breast or ovarian cancer in Japanese subjects.
    Komata D; Yahata T; Kodama S; Koyama Y; Takeda N; Tajima K; Makino H; Sato N; Muto I; Hatakeyama K; Tanaka K
    J Obstet Gynaecol Res; 2009 Oct; 35(5):912-7. PubMed ID: 20149041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.
    Møller P; Evans G; Haites N; Vasen H; Reis MM; Anderson E; Apold J; Hodgson S; Eccles D; Olsson H; Stoppa-Lyonnet D; Chang-Claude J; Morrison PJ; Bevilacqua G; Heimdal K; Maehle L; Lalloo F; Gregory H; Preece P; Borg A; Nevin NC; Caligo M; Steel CM
    Dis Markers; 1999 Oct; 15(1-3):207-11. PubMed ID: 10595280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and benefits of diagnosing familial breast cancer.
    Heimdal K; Maehle L; Møller P
    Dis Markers; 1999 Oct; 15(1-3):167-73. PubMed ID: 10595273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients.
    Fernandes GC; Felicio PS; Michelli RAD; Coelho AS; Scapulatempo-Neto C; Palmero EI
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1655-1660. PubMed ID: 31244284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Distribution of Cancer Genetic Testing in the United States: Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer.
    Childers KK; Maggard-Gibbons M; Macinko J; Childers CP
    JAMA Oncol; 2018 Jun; 4(6):876-879. PubMed ID: 29710084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Implementing B-RST
    Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
    Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
    Chang-Claude J; Dong J; Schmidt S; Shayeghi M; Komitowski D; Becher H; Stratton MR; Royer-Pokora B
    J Med Genet; 1998 Feb; 35(2):116-21. PubMed ID: 9507390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS).
    Peshkin BN; DeMarco TA; Garber JE; Valdimarsdottir HB; Patenaude AF; Schneider KA; Schwartz MD; Tercyak KP
    J Pediatr Psychol; 2009 Jul; 34(6):627-38. PubMed ID: 18385162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
    Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular cancer genetics in eastern and central Europe.
    Olah E
    Dis Markers; 1999 Oct; 15(1-3):75-7. PubMed ID: 10595256
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.